Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 1 · 12.5%Moderate 5 · 62.5%High 0 · 0%

Individual level interventions vs control

Serious adverse events · healthy individuals and those with a pre‐existing health condition

The review found no eligible studies for this question.

1 finding from 1 review

Individual‐level interventions to reduce personal exposure to outdoor air pollution and their effects on people with… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral + inhaled dual therapy vs oral monotherapy

Serious adverse events. Outcome assessed on day 42 · bronchiectasis

It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).

1 finding from 1 review

Dual antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
OR 0.48 [0.08, 2.87]
1 study · 53 participants
Very low

Mepolizumab 300 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 300 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.84 [0.56, 1.27]
1 study · 451 participants
Moderate

Mepolizumab 750 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 750 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 3 [0.22, 40.93]
1 study · 18 participants
Low

Benralizumab 10 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 10 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.9 [0.69, 1.17]
1 study · 1129 participants
Moderate

Benralizumab 30 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 30 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.98 [0.81, 1.17]
2 studies · 2235 participants
Moderate

Benralizumab 100 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Benralizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.9 [0.75, 1.08]
3 studies · 2333 participants
Moderate

Mepolizumab 100 mg vs placebo

Serious adverse events · patients with chronic obstructive pulmonary disease

Mepolizumab 100 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
Odds ratio 0.82 [0.65, 1.05]
2 studies · 1285 participants
Moderate